Volume 4 Supplement 3

6th Drug Hypersensitivity Meeting (DHM 6)

Open Access

HLA-DQ restricted activation of nitroso-sulfamethoxazole-specific CD4+ T-lymphocytes

  • Monday Ogese1,
  • Katy Saide1,
  • Paul Whitaker2,
  • Daniel Peckham2,
  • Lee Faulkner1,
  • Ana Alfirevic1,
  • Munir Pirmohamed1,
  • Kevin Park1 and
  • Dean Naisbitt1
Clinical and Translational Allergy20144(Suppl 3):P110

https://doi.org/10.1186/2045-7022-4-S3-P110

Published: 18 July 2014

Background

Sulfamethoxazole hypersensitivity has been used as a paradigm to study the role of drug metabolism in the activation of T-cells. CD4+ T-cells isolated from blood/skin of 100% of hypersensitive patients are activated with the protein-reactive metabolite nitroso sulfamethoxazole (SMX.NO). Since SMX.NO binds to multiple cellular proteins it is assumed that peptides derived from the modified protein interact with a number of diverse HLA molecules to activate T-cells; however, the HLA molecules that interact with SMX-NO modified peptides has not been studied.

Method

The aims of this study were to examine the HLA molecules that present SMX.NO (derived peptides) to T-cells and determine the extent of alloreactivity. T-cell clones were generated from 4 hypersensitive patients with cystic fibrosis. Drug-specific proliferative responses and cytokine secretion were measured using [3H]-thymidine incorporation and ELISpot, respectively. Anti-human class I and class II (DR, DP, and DQ) antibodies were used to determine HLA restriction. Antigen presenting cells expressing different HLAs were used to define the alleles involved in the presentation of SMX.NO-derived antigens to T-cells.

Results

A total of 976 clones were tested for SMX.NO reactivity. Forty nine CD4+ clones were activated to proliferate and secrete IFN-, IL-5, IL-13 and granzyme-B with SMX.NO. No cross reactivity with SMX was observed. The SMX.NO-specific response of clones was blocked with antibodies against MHC class II and HLA-DQ. Clones from 2 patients (Patient 1: HLA-DQB1*05:01:01G/ DQB1*06:03:01G; Patient 2: HLA-DQB1*02:01:01G/DQB1*02:01:01G) were used to define the DQ alleles involved in the presentation of SMX.NO derived antigens. SMX.NO-specific responses were detected with antigen presenting cells expressing HLA-DQB1*05 (patient 1) and HLA-DQB1*02 (patient 2), but not other HLA-DQB1 alleles.

Conclusion

In conclusion, this study shows that HLA-DQ plays an important role in the activation of SMX.NO-specific T-cells from hypersensitive patients. T-cells from different patients recognized the drug antigen associated with different DQ alleles. However, clones from individual patients were highly DQ allele restricted.

Authors’ Affiliations

(1)
MRC Centre for Drug Safety Science, University of Liverpool
(2)
Regional Adult Cystic Fibrosis Unit, St. James’s Hospital

Copyright

© Ogese et al; licensee BioMed Central Ltd. 2014

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Advertisement